All In Biotech

Drug Trial Radar · NCT04880876

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

A Phase 3, Long-term Safety Study of Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

124

Planned (sponsor's estimate)

Start

Aug 13, 2021

Primary completion

Dec 2032

Study completion Dec 2032

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

Conditions

  • Irritable Bowel Syndrome

Interventions

  • 25mg EluxadolineDrug

    Oral Tablets

  • 100mg EluxadolineDrug

    Oral Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse EventsTime frame: 52 weeks
  2. Percentage of Participants with Clinically Significant Laboratory Values (clinical chemistry, complete blood count, urinalysis) as assessed by the InvestigatorTime frame: 52 weeks
  3. Percentage of Participants with Clinically Significant ECGs as assessed by the InvestigatorTime frame: 52 weeks
  4. Percentage of Participants with Clinically Significant vital sign measurements as assessed by the InvestigatorTime frame: 52 weeks
  5. Percentage of Participants with any new Physical examination abnormality or worsening of change from baselineTime frame: 52 weeks
  6. Percentage of Participants with any new neurological abnormality post baseline or worsening of change from baselineTime frame: 52 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Kindred Medical Institute, LLC /ID# 227595

    Corona, California

  • Valencia Medical & Research Center /ID# 246221

    Miami, Florida

  • Florida Research Center, Inc. /ID# 227597

    Miami, Florida

  • Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600

    Stockbridge, Georgia

  • IPS Research Company /ID# 227594

    Oklahoma City, Oklahoma

  • Preferred Primary Care Physicians, Inc. /ID# 227596

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.